Enzo Biochem Inc represents the values of innovation, excellence, and integrity. The company is committed to advancing scientific research and delivering cutting-edge diagnostic and therapeutic solutions. Enzo Biochem Inc embraces a corporate philosophy centered around quality, accuracy, and collaboration. They strive to provide accurate and reliable products and services to enable healthcare professionals to improve patient outcomes. With a strong focus on research and development, Enzo Biochem Inc aims to address significant unmet medical needs and drive advancements in the field of life sciences.

Enzo Biochem Inc is primarily present in the United States.

Enzo Biochem Inc has achieved several significant milestones throughout its history. In 1976, the company was founded by Dr. Elazar Rabbani and developed innovative technologies for the life sciences and biotechnology sectors. In 1985, Enzo introduced the first commercial oligo synthesizer, revolutionizing DNA research. The company continued to expand its portfolio and in the late 1990s, launched diagnostic products for molecular oncology and genetics. Enzo has also successfully obtained numerous patents for its inventions. Over the years, Enzo Biochem Inc has established itself as a leading player in the life sciences industry with its strong commitment to innovation, research, and development.

Enzo Biochem Inc, founded in 1976, is a leading life sciences and biotechnology company based in New York. It specializes in the development, production, and commercialization of innovative diagnostic and research products worldwide. Enzo Biochem is known for its cutting-edge technology platforms, including gene regulation, therapeutics, and molecular diagnostic systems. The company's focus extends to areas such as biomarkers, infectious diseases, and cancer diagnostics. With a strong history of innovation and a commitment to delivering high-quality products and services, Enzo Biochem continues to play a significant role in advancing the field of life sciences and improving patient care.

The main competitors of Enzo Biochem Inc in the market include companies such as Thermo Fisher Scientific, Quidel Corporation, and Bio-Rad Laboratories.

Enzo Biochem Inc is primarily active in the life sciences and biotechnology industry.

Enzo Biochem Inc is a life sciences and biotechnology company. Its business model encompasses the development, manufacturing, and commercialization of innovative diagnostic and research products. The company offers a diverse range of products and services catering to the life sciences industry. These include molecular diagnostics, immunohistochemistry, flow cytometry, and drug discovery research tools. Enzo Biochem Inc also operates clinical reference laboratories that provide a wide array of testing services. By leveraging its proprietary technology platforms, the company aims to facilitate advancements in personalized medicine and scientific research. Through collaborations and strategic partnerships, Enzo Biochem Inc strives to contribute to advancements in healthcare and improve patient outcomes.

Pašreizējais KGV Enzo Biochem nevar tikt aprēķināts.

KUV šobrīd Enzo Biochem nevar aprēķināt.

AlleAktien kvalitātes vērtējums Enzo Biochem ir 1/10.

Pašreiz nevar aprēķināt apgrozījumu Enzo Biochem.

Pašlaik peļņa Enzo Biochem nevar tikt aprēķināta.

Enzo Biochem Inc is a leading company in the field of life science research, offering a wide range of products and services. The company operates in three main business areas: life sciences, clinical labs, and therapeutics. In the life sciences field, the company provides researchers with a comprehensive range of products and services to better understand the fundamentals of life, including enzymes and proteins, genetic engineering, and immunology. In the clinical lab services area, Enzo Biochem Inc offers specialized testing procedures and preparation technologies to its customers, operating multiple clinical labs in New York and New Jersey. The company also develops a wide range of therapeutics for the treatment of diseases and disorders, based on genetic and biochemical technologies to understand disease mechanisms and develop more effective treatment methods. Enzo Biochem Inc places a strong emphasis on innovation, continuously investing in research and development to provide customers with value-added technologies and methods. Additionally, the company is committed to sustainability and environmental friendliness, developing technologies and products that meet customer requirements while minimizing environmental impact. Overall, Enzo Biochem Inc provides customers with a comprehensive range of products and services to address the challenges of life science research and development, with a focus on innovation and customer satisfaction.

Enzo Biochem izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Enzo Biochem vai uzņēmums nedod dividendes.

Enzo Biochem ISIN ir US2941001024.

Enzo Biochem WKN ir 865607.

Enzo Biochem simbols ir ENZ.

Pēdējo 12 mēnešu laikā Enzo Biochem maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Enzo Biochem plāno maksāt dividendes 0,10 USD apmērā.

Enzo Biochem pašreizējā dividendu rentabilitāte ir .

Enzo Biochem maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Enzo Biochem pēdējo 1 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0,10 USD. Tas atbilst dividendes ražībai 13,74 %.

Enzo Biochem tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Enzo Biochem apmērā 0,1 USD, kas tika izmaksāta 2.12.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 15.11.2024..

Pēdējās dividendes izmaksa notika 2.12.2024..

Gadā 2023, Enzo Biochem izmaksāja 0 USD dividendes.

Enzo Biochem dividendes tiek izmaksātas USD.